Generic Name and Formulations:
Colestipol HCl 5g/pkt or scoop; granules; orange flavored (contains aspartame, phenylalanine) or unflavored.
Indications for COLESTID:
Adjunct to diet to lower elevated serum total-C and LDL-C in primary hypercholesterolemia.
5g–30g daily once or in divided doses mixed with liquid.
Obtain baseline serum cholesterol, LDL-C, and triglycerides, and monitor during therapy. Consider reducing dose, discontinuing, or alternative therapy if significant increase in triglycerides occur. May need Vit. A, D and K supplementation with long-term therapy. Exclude secondary causes of hypercholesterolemia (eg, hypothyroidism, diabetes, nephrotic syndrome, dysproteinemias, obstructive liver disease, alcoholism). Constipation; increase fluid/fiber intake or add a stool softener. Hemorrhoids. Phenylketonurics (flavored Colestid). Monitor thyroid function. Pregnancy. Nursing mothers.
Reduces absorption of folic acid, fat soluble vitamins, thiazides, furosemide, tetracycline, penicillin G, gemfibrozil, mycophenolic acid, others; monitor digitalis, propranolol; give other drugs at least 1hr before or 4hrs after. May affect absorption of oral phosphate supplements, hydrocortisone.
Bile acid sequestrant.
Constipation, fecal impaction, aggravated hemorrhoids, abdominal pain/cramp, gas, indigestion, heartburn, diarrhea, nausea, vomiting, Vit. A, D, K deficiencies or hyperchloremic acidosis with prolonged use.
Unflavored 5g pkt—30, 90; Bulk—300g, 500g (w. scoop); Flavored 7.5g pkt—60; Bulk—450g (w. scoop); Tabs—120
Neurology Advisor Articles
- The Consequences of Compensation in Autism
- Fingolimod May Help Prevent Brain Volume Loss in Relapsing-Remitting Multiple Sclerosis
- Novel Therapy May Improve Symptoms in Early Huntington Disease
- Interaction of Alcohol, Smoking on Multiple Sclerosis Severity
- Demoralization Common in Patients With Parkinson Disease
- Multiple Sclerosis Guidelines: AAN's Recommendations for Initiating, Switching, Stopping Disease-Modifying Therapy
- Migraine a Common Comorbidity in Individuals With Sarcoidosis
- Cardiovascular Risk Factors and Development of Brain Atrophy in Multiple Sclerosis
- Association Between Multiple Sclerosis Relapses and Vaccinations
- Understanding Impulse Control Disorders in Parkinson Disease: Developments and Treatments